References
- Goldhirsch A., Wood W., Gelber R., et al. Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357–65
- Tokunaga E., Oki E., Nishida K., et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11: 199–208
- Australian Cancer Network. 2001. The Pathology Reporting of Breast Cancer. A Guide for Pathologists, Surgeons, Radiologists and Oncologists. IntraMed Educational Group. http://www.cancer.org.au/documents/The_Pathology_reporting_of_breast_cancer_2001.pdf (accessed Aug 2006)
- Bilous M., Dowsett M., Hanna W., et al. Current perspectives on HER2 testing: a review of the national testing guidelines. Mod Pathol 2003; 16: 173–82
- Burge C., Chang H., Apple S. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?. Breast 2006; 15: 167–72
- Mann G., Fahey V., Feleppa F., et al. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005; 23: 5148–54
- Allred D., Harvey J., Berardo M., et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155–68
- Osborne C., Yochmowitz M., Knight W., et al. The value of oestrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884–8
- Osborne C., Schiff R., Arpino G., et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005; 14: 458–65
- Layfield L., Gupta D., Mooney E. Assessment of tissue estrogen and progesterone receptor levels: a survey of current practice, techniques and quantitation methods. Breast J 2000; 6: 189–96
- Rhodes A., Jasani B., Barnes D., et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125–30
- Douglas‐Jones A., Collett N., Morgan J., et al. Comparison of oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of Er in breast carcinoma. J Clin Pathol 2001; 54: 951–5
- Cahill R., Walsh D Landers R., et al. Preoperative profiling of symptomatic breast cancer by diagnostic core biopsy. Ann Surg Oncol 2006; 13: 45–51
- Tubbs R., Pettay J., Roche P., et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent false positives do not get the message. J Clin Oncol 2001; 19: 2714–21
- Loring P., Cummins R., O'Grady A., et al. HER2 positivity in breast carcinoma: A comparison of chromogenic in situ hybridization with fluorescence in situ hybridization in tissue microarrays, with targeted evaluation of intratumoral heterogeneity. Appl Immunhistochem Mol Morphol 2005; 13: 194–200